세계의 재생의료 시장 : 제품 유형별, 재료별, 유전자 변형 재료별, 용도별, 최종 사용자별, 지역별, 시장 규모, 산업 동향, 기회 분석과 예측(2025-2033년)

The regenerative medicine market is undergoing remarkable expansion, with projections indicating a dramatic rise in its global valuation over the coming decade. In 2024, the market was valued at approximately US$ 73.01 billion, and this figure is expected to surge to an estimated US$ 578.59 billion by 2033. This growth corresponds to a robust compound annual growth rate (CAGR) of 25.86% during the forecast period from 2025 to 2033. Such an impressive trajectory is primarily driven by significant advancements in key technologies like stem cell therapy, gene editing, and tissue engineering.

The market's growth, however, is characterized by notable regional disparities that influence the pace of investment and patient access to therapies. North America remains at the forefront, benefiting from the most developed clinical infrastructure for regenerative treatments. By mid-2024, approximately 400 specialized centers had received certification to administer autologous cell therapies, underscoring the region's advanced capabilities in delivering personalized regenerative care. Furthermore, eight U.S. states had enacted legislation mandating value-based agreements, which help mitigate the financial burden of high upfront costs associated with these innovative treatments. This regulatory and clinical framework supports sustainable adoption and reimbursement models, enabling broader patient access.

Noteworthy Market Developments

The competitive landscape of the regenerative medicine market is dominated by well-established biopharmaceutical giants who are harnessing cutting-edge technologies to drive innovation and expand their global reach. Medtronic Plc stands out as a leader, with operations spanning over 150 countries and a workforce of approximately 90,000 professionals. This extensive global presence enables Medtronic to leverage diverse markets and expertise, positioning the company at the forefront of regenerative medicine advancements.

Other major players shaping the market include AbbVie Inc., Amgen Inc., and Novartis Pharma AG, each distinguished by their substantial investments in research and development. These companies continuously push the boundaries of regenerative therapies, driving breakthroughs that address a wide range of medical conditions. Their commitment to R&D fuels innovation pipelines, ensuring a steady flow of novel treatments that enhance patient care.

Core Growth Drivers

The regenerative medicine market is currently experiencing an unprecedented surge in regulatory approvals, a development that is fundamentally reshaping therapeutic accessibility for millions of patients around the globe. Throughout 2024, regulatory agencies across key international markets have accelerated their approval processes to keep pace with the rapid advancements in regenerative therapies. In particular, the U.S. Food and Drug Administration (FDA) has played a pivotal role by granting breakthrough therapy designations to more than 15 novel cell and gene therapies within just the first three quarters of the year.

Similarly, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) continues to set a global standard with its progressive conditional approval framework. This regulatory approach allows regenerative medicine products to enter the market early once they have demonstrated safety and a probable benefit, even if comprehensive efficacy data is still being collected. This policy not only encourages innovation but also facilitates faster patient access to potentially life-changing treatments.

Emerging Opportunity Trends

The convergence of artificial intelligence (AI) with regenerative medicine is fundamentally transforming therapeutic development timelines and patient outcomes by leveraging unprecedented computational power. This integration spans the entire regenerative medicine value chain, from initial discovery and research to manufacturing optimization and ongoing patient monitoring. AI's ability to analyze vast datasets rapidly and accurately is accelerating the identification of novel therapeutic targets, optimizing complex manufacturing processes, and enabling real-time, personalized patient care.

Real-world applications of AI within regenerative medicine illustrate its transformative impact on clinical practice. For instance, Massachusetts General Hospital has implemented an AI-driven monitoring system that continuously tracks the health status of 3,500 patients undergoing stem cell therapy. This innovative system is capable of detecting early signs of transplant rejection up to 72 hours before symptoms become clinically apparent, allowing for timely interventions that significantly improve patient outcomes.

Barriers to Optimization

Manufacturing challenges represent the most formidable obstacle to the expansion of the regenerative medicine market, significantly limiting patient access despite a growing number of therapeutic approvals. The complexity of producing advanced cell and gene therapies demands specialized facilities that comply with stringent Good Manufacturing Practice (GMP) standards, requiring capital investments exceeding US$ 250 million for each production line. In addition to these upfront costs, operational expenses remain exceptionally high, with treatment costs reaching approximately US$ 85,000 per patient.

These financial and technical barriers create significant bottlenecks in scaling production to meet the rapidly increasing demand. One of the most critical constraints lies in the production of viral vectors, which are essential components for many gene therapies. Currently, global manufacturing capacity can only accommodate around 35,000 patient doses annually, a figure vastly insufficient compared to the estimated demand of 180,000 treatments. This shortfall presents a major hurdle in delivering life-changing therapies to patients in a timely manner.

Detailed Market Segmentation

By Product Type, stem cell therapy continues to hold a dominant position in the global regenerative medicine market, capturing a significant 34.64% share during the 2024-2025 period. This strong market presence is fueled by groundbreaking clinical applications and the ongoing expansion of therapeutic capabilities that stem cell technologies offer. Among these advances, induced pluripotent stem cell (iPSC) technology stands out as a revolutionary development that has significantly broadened the scope and effectiveness of stem cell therapies. iPSCs, which are adult cells reprogrammed to an embryonic-like state, enable the generation of a wide variety of specialized cell types, offering unprecedented potential for treating complex diseases.

By Material, biologically derived materials hold a dominant position in the regenerative medicine market, commanding an impressive 54.77% share during 2024-2025 and projecting the highest compound annual growth rate (CAGR) of 26.30%. This leadership is rooted in the unparalleled biocompatibility and therapeutic efficacy that biologically sourced materials offer, making them the preferred choice for a wide range of regenerative applications. The segment's prominence is particularly evident in the groundbreaking advancements in extracellular matrix (ECM) technologies, which provide essential scaffolding and bioactive cues to support tissue repair and regeneration.

By Application, the oncology segment continues to hold a commanding position in the regenerative medicine market, capturing a substantial 49.22% share during the 2024-2025 period. This dominance is largely driven by revolutionary advancements such as CAR-T cell therapies and other innovative cancer treatment modalities that are dramatically improving patient outcomes. These breakthroughs represent a paradigm shift in how hematological malignancies and certain solid tumors are treated, offering new hope to patients who previously had limited options.

By End Users, hospitals and clinics have firmly established themselves as the dominant end users in the regenerative medicine market, commanding a significant market share of 43.57% during 2024-2025. This impressive position is underpinned by a robust compound annual growth rate (CAGR) of 26.37%, highlighting the rapid expansion and increasing adoption of regenerative medicine within these healthcare settings. As primary delivery centers for advanced regenerative therapies, hospitals and clinics have been making substantial infrastructure investments worldwide, totaling over US$ 8.5 billion.

Segment Breakdown

By Product Type

• Gene Therapy
• Cell Therapy
• Stem Cell Therapy
  • Autologous Therapy
  • Allogenic Therapy
• Tissue-Engineering
• Small Molecules & Biologics
• Others

By Material

• Synthetic material
  • Biodegradable synthetic polymers
  • Scaffold
  • Artificial Vascular Graft
  • Hydrogel Material
  • Others
• Biologically derived material
  • Collagen
  • Xenogeneic material
  • Others
• Genetically Engineered Material
  • Genetically Manipulated Cell
  • Transgenics
  • Fibroblast
  • Neural Stem Cell
  • Gene-Activated Matrices
  • Others
• Pharmaceutical
  • Biologics
  • Small Molecules
  • Others

By Application

• Dermatology
• Musculoskeletal
• Immunology & Inflammation
• Oncology
• Cardiovascular
• Neurology
• Ophthalmology
• Others

By End User

• Hospitals & Clinics
• Speciality Centers
• Government & Academic Research Institutes
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Poland
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • ASEAN
    • Malaysia
    • Singapore
    • Thailand
    • Indonesia
    • Philippines
    • Vietnam
    • Rest of ASEAN
  • Rest of Asia Pacific
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America

Leading Market Participants

• Allergan PLC
• Baxter International Inc
• Bayer AG
• Boehringer Ingelheim
• Cesca Therapeutics, Inc.
• F. Hoffmann-La Roche Ltd.
• Fujifilm Corporation
• Medtronic plc
• Merck KGaA
• Mimedx Group Inc
• Novartis AG
• Organogenesis, Inc.
• Osiris Therapeutics
• Pfizer, Inc.
• Takara Bio Inc.
• U.S. Stem Cell, Inc.
• Other Prominent Players

Table of Content

Chapter 1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

Chapter 2. Research Methodology

• 2.1. Qualitative Research
  • 2.1.1. Primary & Secondary Sources
• 2.2. Quantitative Research
  • 2.2.1. Primary & Secondary Sources
• 2.3. Breakdown of Primary Research Respondents, By Region
• 2.4. Assumption for the Study
• 2.5. Market Size Estimation
• 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Regenerative Medicine Market

Chapter 4. Global Regenerative Medicine Market Overview

• 4.1. Industry Value Chain Analysis
  • 4.1.1. Material Provider
  • 4.1.2. Manufacturer
  • 4.1.3. Distributor
  • 4.1.4. End User
• 4.2. Supply chain of regenerative medicine
  • 4.2.1. Cell Sourcing and Collection
  • 4.2.2. Quality Control and Testing
  • 4.2.3. Manufacturing and Processing
  • 4.2.4. Clinical Trials and Regulatory Approval
  • 4.2.5. Patient Administration
  • 4.2.6. Post-Market Surveillance
• 4.3. Industry Outlook
  • 4.3.1. Advances in Regenerative Medicine and Tissue Engineering
  • 4.3.2. Regulation of Regenerative Medicine in Japan
  • 4.3.3. Dissemination of Regenerative Medicine in Japan
  • 4.3.4. Overview: Japan Strengthens Regenerative Medicine Oversight
  • 4.3.5. Regenerative Medicine at a Global Level: Current Patterns and Global Trends
  • 4.3.6. Comparative lessons in regenerative medicine readiness: UK and Japan Case Study
  • 4.3.7. A comparative analysis of attitudes toward stem cell research and regenerative medicine between six countries (Japan, South Korea, the USA, the UK, Germany, and France)
• 4.4. PESTLE Analysis
• 4.5. Porter's Five Forces Analysis
  • 4.5.1. Bargaining Power of Suppliers
  • 4.5.2. Bargaining Power of Buyers
  • 4.5.3. Threat of Substitutes
  • 4.5.4. Threat of New Entrants
  • 4.5.5. Degree of Competition
• 4.6. Market Dynamics and Trends
  • 4.6.1. Growth Drivers
  • 4.6.2. Restraints
  • 4.6.3. Challenges
  • 4.6.4. Key Trend
• 4.7. Covid-19 Impact Assessment on Market Growth Trend
• 4.8. Market Growth and Outlook
  • 4.8.1. Market Revenue Estimates and Forecast (US$ Bn), 2020 - 2033
  • 4.8.2. Price Trend Analysis, By Product Type
• 4.9. Competition Dashboard
  • 4.9.1. Market Concentration Rate
  • 4.9.2. Company Market Share Analysis (Value %), 2024
  • 4.9.3. Competitor Mapping

Chapter 5. Global Regenerative Medicine Market Analysis, By Product Type

• 5.1. Key Insights
• 5.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 5.2.1. Gene Therapy
  • 5.2.2. Cell Therapy
  • 5.2.3. Stem Cell Therapy
    • 5.2.3.1. Autologous Therapy
    • 5.2.3.2. Allogenic Therapy
  • 5.2.4. Tissue-Engineering
  • 5.2.5. Small Molecules & Biologics
  • 5.2.6. Others

Chapter 6. Global Regenerative Medicine Market Analysis, By Material

• 6.1. Key Insights
• 6.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 6.2.1. Synthetic material
    • 6.2.1.1. Biodegradable synthetic polymers
    • 6.2.1.2. Scaffold
    • 6.2.1.3. Artificial Vascular Graft
    • 6.2.1.4. Hydrogel Material
    • 6.2.1.5. Others
  • 6.2.2. Biologically derived material
    • 6.2.2.1. Collagen
    • 6.2.2.2. Xenogeneic material
    • 6.2.2.3. Others
  • 6.2.3. Genetically Engineered Material
    • 6.2.3.1. Genetically Manipulated Cell
    • 6.2.3.2. Transgenics
    • 6.2.3.3. Fibroblast
    • 6.2.3.4. Neural Stem Cell
    • 6.2.3.5. Gene-Activated Matrices
    • 6.2.3.6. Others
  • 6.2.4. Pharmaceutical
    • 6.2.4.1. Biologics
    • 6.2.4.2. Small Molecules
    • 6.2.4.3. Others

Chapter 7. Global Regenerative Medicine Market Analysis, By Application

• 7.1. Key Insights
• 7.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 7.2.1. Dermatology
  • 7.2.2. Musculoskeletal
  • 7.2.3. Immunology & Inflammation
  • 7.2.4. Oncology
  • 7.2.5. Cardiovascular
  • 7.2.6. Neurology
  • 7.2.7. Ophthalmology
  • 7.2.8. Others

Chapter 8. Global Regenerative Medicine Market Analysis, By End User

• 8.1. Key Insights
• 8.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 8.2.1. Hospitals & Clinics
  • 8.2.2. Speciality Centers
  • 8.2.3. Government & Academic Research Institutes
  • 8.2.4. Others

Chapter 9. Global Regenerative Medicine Market Analysis, By Region

• 9.1. Key Insights
• 9.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 9.2.1. North America
    • 9.2.1.1. The U.S.
    • 9.2.1.2. Canada
    • 9.2.1.3. Mexico
  • 9.2.2. Europe
    • 9.2.2.1.1. The UK
    • 9.2.2.1.2. Germany
    • 9.2.2.1.3. France
    • 9.2.2.1.4. Italy
    • 9.2.2.1.5. Spain
    • 9.2.2.1.6. Poland
    • 9.2.2.1.7. Russia
    • 9.2.2.1.8. Rest of Europe
  • 9.2.3. Asia Pacific
    • 9.2.3.1. China
    • 9.2.3.2. India
    • 9.2.3.3. Japan
    • 9.2.3.4. South Korea
    • 9.2.3.5. Australia & New Zealand
    • 9.2.3.6. ASEAN
    • 9.2.3.7. Rest of Asia Pacific
  • 9.2.4. Middle East & Africa
    • 9.2.4.1. UAE
    • 9.2.4.2. Saudi Arabia
    • 9.2.4.3. South Africa
    • 9.2.4.4. Rest of MEA
  • 9.2.5. South America
    • 9.2.5.1. Argentina
    • 9.2.5.2. Brazil
    • 9.2.5.3. Rest of South America

Chapter 10. North America Regenerative Medicine Market Analysis

• 10.1. Key Insights
• 10.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 10.2.1. By Product Type
  • 10.2.2. By Material
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country

Chapter 11. The U.S. Regenerative Medicine Market Analysis

• 11.1. Key Insights
• 11.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 11.2.1. By Product Type
  • 11.2.2. By Material
  • 11.2.3. By Application
  • 11.2.4. By End User

Chapter 12. Canada Regenerative Medicine Market Analysis

• 12.1. Key Insights
• 12.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 12.2.1. By Product Type
  • 12.2.2. By Material
  • 12.2.3. By Application
  • 12.2.4. By End User

Chapter 13. Mexico Regenerative Medicine Market Analysis

• 13.1. Key Insights
• 13.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 13.2.1. By Product Type
  • 13.2.2. By Material
  • 13.2.3. By Application
  • 13.2.4. By End User

Chapter 14. Europe Regenerative Medicine Market Analysis

• 14.1. Key Insights
• 14.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 14.2.1. By Product Type
  • 14.2.2. By Material
  • 14.2.3. By Application
  • 14.2.4. By End User
  • 14.2.5. By Country

Chapter 15. The UK Regenerative Medicine 16.1. Key Insights

• 15.1. Key Insights
• 15.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 15.2.1. By Product Type
  • 15.2.2. By Material
  • 15.2.3. By Application
  • 15.2.4. By End User

Chapter 16. Germany Regenerative Medicine Market Analysis

• 16.1. Key Insights
• 16.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 16.2.1. By Product Type
  • 16.2.2. By Material
  • 16.2.3. By Application
  • 16.2.4. By End User

Chapter 17. France Regenerative Medicine Market Analysis

• 17.1. Key Insights
• 17.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 17.2.1. By Product Type
  • 17.2.2. By Material
  • 17.2.3. By Application
  • 17.2.4. By End User

Chapter 18. Italy Regenerative Medicine Market Analysis

• 18.1. Key Insights
• 18.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 18.2.1. By Product Type
  • 18.2.2. By Material
  • 18.2.3. By Application
  • 18.2.4. By End User

Chapter 19. Spain Regenerative Medicine Market Analysis

• 19.1. Key Insights
• 19.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 19.2.1. By Product Type
  • 19.2.2. By Material
  • 19.2.3. By Application
  • 19.2.4. By End User

Chapter 20. Poland Regenerative Medicine Market Analysis

• 20.1. Key Insights
• 20.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 20.2.1. By Product Type
  • 20.2.2. By Material
  • 20.2.3. By Application
  • 20.2.4. By End User

Chapter 21. Russia Regenerative Medicine Market Analysis

• 21.1. Key Insights
• 21.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 21.2.1. By Product Type
  • 21.2.2. By Material
  • 21.2.3. By Application
  • 21.2.4. By End User

Chapter 22. Rest of Europe Regenerative Medicine Market Analysis

• 22.1. Key Insights
• 22.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 22.2.1. By Product Type
  • 22.2.2. By Material
  • 22.2.3. By Application
  • 22.2.4. By End User

Chapter 23. Asia Pacific Regenerative Medicine Market Analysis

• 23.1. Key Insights
• 23.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 23.2.1. By Product Type
  • 23.2.2. By Material
  • 23.2.3. By Application
  • 23.2.4. By End User
  • 23.2.5. By Country

Chapter 24. China Regenerative Medicine Market Analysis

• 24.1. Key Insights
• 24.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 24.2.1. By Product Type
  • 24.2.2. By Material
  • 24.2.3. By Application
  • 24.2.4. By End User

Chapter 25. India Regenerative Medicine Market Analysis

• 25.1. Key Insights
• 25.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 25.2.1. By Product Type
  • 25.2.2. By Material
  • 25.2.3. By Application
  • 25.2.4. By End User

Chapter 26. Japan Regenerative Medicine Market Analysis

• 26.1. Key Insights
• 26.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 26.2.1. By Product Type
  • 26.2.2. By Material
  • 26.2.3. By Application
  • 26.2.4. By End User

Chapter 27. South Korea Regenerative Medicine Market Analysis

• 27.1. Key Insights
• 27.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 27.2.1. By Product Type
  • 27.2.2. By Material
  • 27.2.3. By Application
  • 27.2.4. By End User

Chapter 28. Australia & New Zealand Regenerative Medicine Market Analysis

• 28.1. Key Insights
• 28.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 28.2.1. By Product Type
  • 28.2.2. By Material
  • 28.2.3. By Application
  • 28.2.4. By End User

Chapter 29. ASEAN Regenerative Medicine Market Analysis

• 29.1. Key Insights
• 29.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 29.2.1. By Product Type
  • 29.2.2. By Material
  • 29.2.3. By Application
  • 29.2.4. By End User

Chapter 30. Rest of Asia Pacific Regenerative Medicine Market Analysis

• 30.1. Key Insights
• 30.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 30.2.1. By Product Type
  • 30.2.2. By Material
  • 30.2.3. By Application
  • 30.2.4. By End User

Chapter 31. Middle East and Africa Regenerative Medicine Market Analysis

• 31.1. Key Insights
• 31.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 31.2.1. By Product Type
  • 31.2.2. By Material
  • 31.2.3. By Application
  • 31.2.4. By End User
  • 31.2.5. By Country

Chapter 32. UAE Regenerative Medicine Market Analysis

• 32.1. Key Insights
• 32.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 32.2.1. By Product Type
  • 32.2.2. By Material
  • 32.2.3. By Application
  • 32.2.4. By End User

Chapter 33. Saudi Arabia Regenerative Medicine Market Analysis

• 33.1. Key Insights
• 33.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 33.2.1. By Product Type
  • 33.2.2. By Material
  • 33.2.3. By Application
  • 33.2.4. By End User

Chapter 34. South Africa Regenerative Medicine Market Analysis

• 34.1. Key Insights
• 34.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 34.2.1. By Product Type
  • 34.2.2. By Material
  • 34.2.3. By Application
  • 34.2.4. By End User

Chapter 35. Rest of MEA Regenerative Medicine Market Analysis

• 35.1. Key Insights
• 35.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 35.2.1. By Product Type
  • 35.2.2. By Material
  • 35.2.3. By Application
  • 35.2.4. By End User

Chapter 36. South America Regenerative Medicine Market Analysis

• 36.1. Key Insights
• 36.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 36.2.1. By Product Type
  • 36.2.2. By Material
  • 36.2.3. By Application
  • 36.2.4. By End User
  • 36.2.5. By Country

Chapter 37. Argentina Regenerative Medicine Market Analysis

• 37.1. Key Insights
• 37.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 37.2.1. By Product Type
  • 37.2.2. By Material
  • 37.2.3. By Application
  • 37.2.4. By End User

Chapter 38. Brazil Regenerative Medicine Market Analysis

• 38.1. Key Insights
• 38.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 38.2.1. By Product Type
  • 38.2.2. By Material
  • 38.2.3. By Application
  • 38.2.4. By End User

Chapter 39. Rest of South America Regenerative Medicine Market Analysis

• 39.1. Key Insights
• 39.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
  • 39.2.1. By Product Type
  • 39.2.2. By Material
  • 39.2.3. By Application
  • 39.2.4. By End User

Chapter 40. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

• 40.1. Allergan PLC
• 40.2. Baxter International Inc
• 40.3. Bayer AG
• 40.4. Boehringer Ingelheim
• 40.5. Cesca Therapeutics, Inc.
• 40.6. F. Hoffmann-La Roche Ltd.
• 40.7. Fujifilm Corporation
• 40.8. Medtronic plc
• 40.9. Merck KGaA
• 40.10. Mimedx Group Inc
• 40.11. Novartis AG
• 40.12. Organogenesis, Inc.
• 40.13. Osiris Therapeutics
• 40.14. Pfizer, Inc.
• 40.15. Takara Bio Inc.
• 40.16. U.S. Stem Cell, Inc.
• 40.17. Other Prominent Players